Tafinlar and Haematuria - a phase IV clinical study of FDA data

Summary:

Haematuria is reported as a side effect among people who take Tafinlar (dabrafenib mesylate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Mekinist, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Haematuria when taking Tafinlar. It is created by eHealthMe based on reports of 16,296 people who have side effects when taking Tafinlar from the FDA, and is updated regularly.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 16,304 Tafinlar users. Check the latest studies of Tafinlar.

What is Haematuria?

Haematuria (presence of blood in urine) is found to be associated with 1,705 drugs and 2,519 conditions by eHealthMe. Check the latest studies of Haematuria.

On Jul, 18, 2026

16,296 people reported to have side effects when taking Tafinlar.
Among them, 44 people (0.27%) have Haematuria.

Among these 44 people:

How long have people been on Tafinlar when they have Haematuria? *

What is the gender of people who have Haematuria when taking Tafinlar? *

female: 41.46 %
male: 58.54 %

What is the age of people who have Haematuria when taking Tafinlar? *

What are other drugs people take besides Tafinlar? *

What are other side effects people have besides Haematuria? *

Fever: 22 people, 50.00%
Nausea (feeling of having an urge to vomit): 13 people, 29.55%
Rashes (redness): 11 people, 25.00%
Urinary Tract Infection: 10 people, 22.73%
Oedema Peripheral (superficial swelling): 10 people, 22.73%
Fatigue (feeling of tiredness): 10 people, 22.73%
Nosebleed (bleeding from nose): 9 people, 20.45%
Diarrhea: 9 people, 20.45%
Influenza Like Illness: 8 people, 18.18%
Leukopenia (less number of white blood cells in blood): 7 people, 15.91%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 20 people, 45.45%
Malignant Melanoma (skin cancer rises from melancytes): 19 people, 43.18%
Diarrhea: 6 people, 13.64%
High Blood Pressure: 5 people, 11.36%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 9.09%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 4 people, 9.09%
Migraine (headache): 4 people, 9.09%
Undifferentiated Sarcoma (undifferentiated cancer): 3 people, 6.82%
Metastases To Bone (cancer spreads to bone): 3 people, 6.82%
Metastases To Lung (cancer spreads to lung): 3 people, 6.82%

* Approximation only. Some reports may have incomplete information.

Do you take Tafinlar and have Haematuria?

- Check whether Haematuria is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tafinlar:

Tafinlar (16,304 reports)

Haematuria treatments and more:

Haematuria (44,248 reports)

Browse all side effects of Tafinlar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematuria:

Haematuria (1,705 drugs)

Browse all the conditions that are associated with Haematuria:

Haematuria (2,519 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dabrafenib mesylate (the active ingredients of Tafinlar) and Tafinlar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.